Clinical trials: Mask
Branch Retinal Vein Occlusion
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in…
- Trial name
- VIBRANT (NCT01521559)
- Testing
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 183 people
- Sponsor
- Regeneron Pharmaceuticals
Wet Age Related Macular Degeneration, wAMD
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
- Trial name
- wAMD (NCT06683742)
- Testing
- EYP-1901, Aflibercept (2.0 mg)
- Where
- 113 sites in United States, Brazil and 8 more
- Volunteers
- 400 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
The purpose of this study was to evaluate the efficacy and safety of brolucizumab compared to panretinal photocoagulation laser (PRP) in patients with proliferative diabetic retinopathy (PDR).
- Trial name
- CONDOR (NCT04278417)
- Testing
- Brolucizumab 6 mg, Panretinal photocoagulation laser
- Where
- 120 sites in United States, Argentina and 14 more
- Volunteers
- 689 people
- Sponsor
- Novartis Pharmaceuticals
Elevated Intraocular Pressure
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to…
- Trial name
- TC-002-301 (NCT05165290)
- Testing
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- TearClear Corp
Vitrectomy
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.
- Trial name
- MIC (NCT00986362)
- Testing
- Ocriplasmin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- ThromboGenics
Chronic Graft-versus-host Disease
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
To assess the efficacy of R348 Ophthalmic Solutions administered for 12 weeks to subjects evaluated by objective and subjective measures.
- Trial name
- DROPS-2 (NCT02040623)
- Testing
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rigel Pharmaceuticals
Healthy
A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults
This study will compare the bioavailability of a novel powder for oral suspension formulation of delafloxacin, intended for treatment of community acquired bacterial pneumonia, to that of the licensed delafloxacin oral tablet in…
- Trial name
- NCT06612255
- Testing
- Delafloxacin, Delafloxacin Powder
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Presbyopia
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
Presbyopia is a condition in which the eye exhibits a diminished ability to focus on near objects with increasing age. This study will assess the safety and exploratory efficacy of AGN-190584 is in treating participants with…
- Trial name
- ARIES (NCT05393089)
- Testing
- AGN-190584, Vehicle
- Where
- 32 sites in United States
- Sponsor
- Allergan
Non-Proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
The purpose of this trial is to study the safety and effectiveness of OTX-TKI (axitinib intravitreal hydrogel) for the treatment of Non-Proliferative Diabetic Retinopathy.
- Trial name
- HELIOS-3 (NCT07235085)
- Testing
- Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24
- Where
- United States
- Volunteers
- 930 people
- Sponsor
- Ocular Therapeutix, Inc.
Myopia, Progressive, Myopia
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression
This is a monocenter, randomized, controlled, parallel-group, double-masked clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation at baseline compared to a…
- Trial name
- NCT05331378
- Testing
- Test myopia control lenses, Single vision lenses
- Where
- Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Essilor International
Long Term Follow up Dry Eye Disease
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
The objective of this safety long-term follow-up study was to evaluate the safety of OC-01 Nasal Spray at 6 months and 12 months post treatment in the OPP-002 study (NCT03636061).
- Trial name
- NCT03920215
- Testing
- OC-01 Low Dose, 0.12 mg/mL, OC-01 Mid Dose, 0.6 mg/mL, OC-01 High Dose, 1.2 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Oyster Point Pharma, Inc.
Neurotrophic Keratitis
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
The primary objective of this study is to evaluate the efficacy of 20 µg/ml 6 times a day of rhNGF eye drops solution (formulation containing anti-oxidant) compared to vehicle (formulation containing anti-oxidant) given 6 times a…
- Trial name
- NCT02227147
- Testing
- rhNGF 20µg/ml
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- Dompé Farmaceutici S.p.A
Keratoconus
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
- Trial name
- NCT07400952
- Testing
- GLK-221 Ophthalmic Solution
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Glaukos Corporation
Thyroid Eye Disease
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
- Trial name
- spiriTED (NCT06088979)
- Testing
- TOUR006 - 20 MG, TOUR006 - 50 MG
- Where
- 36 sites in United States, Brazil and 9 more
- Volunteers
- 79 people
- Sponsor
- Tourmaline Bio, Inc., a Novartis Company
Macular Edema, Retinal Vein Occlusion
Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina
This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
- Trial name
- FAVOR (NCT00770770)
- Testing
- Fluocinolone Acetonide
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Alimera Sciences
Glaucoma
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
- Trial name
- NCT00716859
- Testing
- Timolol, latanoprost
- Where
- 48 sites in United States, Belgium and 18 more
- Volunteers
- 139 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Neovascular Age-Related Macular Degeneration
A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port…
- Trial name
- Archway (NCT03677934)
- Testing
- PDS Implant filled with 100 mg/mL Ranibizumab, Intravitreal Injections of 10 mg/mL Ranibizumab
- Where
- 77 sites in United States
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Dry Eye
Phase 3 Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease
This is a phase 3 study to evaluate the safety and efficacy of OmegaD softgels for the treatment of dry eye disease. A daily dose of 2 OmegaD softgels dosed orally BID will be compared to 2 placebo softgels (mineral oil ) dosed…
- Trial name
- NCT04181593
- Testing
- Omega 3 fatty acid
- Where
- 14 sites in United States
- Volunteers
- 322 people
- Sponsor
- OmegaD LLC
Dry Eye Disease
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
- Trial name
- NCT06424444
- Testing
- Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution
- Where
- United States
- Volunteers
- 421 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Raised Intraocular Pressure
A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure
The purpose of this study is to evaluate the efficacy of systemically administered AZD4017, compared with placebo, over a 28-day period in patients with raised intra-ocular pressure (IOP).
- Trial name
- NCT01173471
- Testing
- AZD4017
- Where
- 11 sites in United States, Sweden and 1 more
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.